Abstract：
UNASSIGNED: The use of nebulized tranexamic acid (TXA) in massive pulmonary hemorrhage is well-described. Published utilization in post-tonsillectomy bleeding (PTB) is limited to a single case. This study examines whether TXA resulted in change of operative intervention necessity and narcotic utilization.
UNASSIGNED: This was a retrospective cohort study at a single, urban academic medical center in the United States. Chart review was conducted of all patients who presented to the hospital for post-tonsillectomy bleed (PTB) between 3/1/2018 and 7/1/2020. Demographic data, intervention modality, need for control under general anesthesia, and opioid use were collected and analyzed.
UNASSIGNED: Twenty-one patients underwent a total of 23 visits for PTB over the study period. Control of hemorrhage without need for operating room intervention for PTB was 100% (6/6) for patients receiving TXA nebulizer and 53% (9/17) for those receiving other treatment modalities. Opioid usage in hospital and on discharge was also lower in patients receiving TXA nebulizers. All results were statistically significant.
UNASSIGNED: Our study supports nebulized TXA as an effective, non-invasive mode of hemostasis in patients presenting to the emergency department for post-tonsillectomy hemorrhage. Nebulized TXA may prevent the need for general anesthesia and operative intervention. Otolaryngologists should consider addition of this novel treatment appropriation of TXA to their management options for postoperative tonsillar hemorrhage.
UNASSIGNED: This was a retrospective cohort study at a single, urban academic medical center in the United States. Chart review was conducted of all patients who presented to the hospital for post-tonsillectomy bleed (PTB) between 3/1/2018 and 7/1/2020. Demographic data, intervention modality, need for control under general anesthesia, and opioid use were collected and analyzed.
UNASSIGNED: Twenty-one patients underwent a total of 23 visits for PTB over the study period. Control of hemorrhage without need for operating room intervention for PTB was 100% (6/6) for patients receiving TXA nebulizer and 53% (9/17) for those receiving other treatment modalities. Opioid usage in hospital and on discharge was also lower in patients receiving TXA nebulizers. All results were statistically significant.
UNASSIGNED: Our study supports nebulized TXA as an effective, non-invasive mode of hemostasis in patients presenting to the emergency department for post-tonsillectomy hemorrhage. Nebulized TXA may prevent the need for general anesthesia and operative intervention. Otolaryngologists should consider addition of this novel treatment appropriation of TXA to their management options for postoperative tonsillar hemorrhage.
摘要：
■雾化氨甲环酸（TXA）在大量肺出血中的应用已得到充分描述。扁桃体切除术后出血（PTB）的公开使用仅限于单个病例。这项研究考察了TXA是否导致手术干预必要性和麻醉剂利用率的变化。
■这是一项回顾性队列研究，美国城市学术医疗中心。对2018年3月1日至2020年7月1日期间到医院接受扁桃体切除术后出血（PTB）的所有患者进行图表审查。人口统计数据,干预方式，在全身麻醉下需要控制，收集和分析阿片类药物的使用情况。
■21名患者在研究期间共进行了23次PTB访视。接受TXA雾化器的患者在不需要手术室干预的情况下控制出血为100％（6/6），接受其他治疗方式的患者为53％（9/17）。接受TXA雾化器的患者在医院和出院时的阿片类药物使用量也较低。所有结果均具有统计学意义。
■我们的研究支持雾化TXA作为一种有效的，非侵入性止血模式的患者出现在急诊科的扁桃体切除术后出血。雾化TXA可以防止全身麻醉和手术干预的需要。耳鼻喉科医师应考虑在术后扁桃体出血的治疗选择中增加TXA的这种新颖治疗方法。
■这是一项回顾性队列研究，美国城市学术医疗中心。对2018年3月1日至2020年7月1日期间到医院接受扁桃体切除术后出血（PTB）的所有患者进行图表审查。人口统计数据,干预方式，在全身麻醉下需要控制，收集和分析阿片类药物的使用情况。
■21名患者在研究期间共进行了23次PTB访视。接受TXA雾化器的患者在不需要手术室干预的情况下控制出血为100％（6/6），接受其他治疗方式的患者为53％（9/17）。接受TXA雾化器的患者在医院和出院时的阿片类药物使用量也较低。所有结果均具有统计学意义。
■我们的研究支持雾化TXA作为一种有效的，非侵入性止血模式的患者出现在急诊科的扁桃体切除术后出血。雾化TXA可以防止全身麻醉和手术干预的需要。耳鼻喉科医师应考虑在术后扁桃体出血的治疗选择中增加TXA的这种新颖治疗方法。
